Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | SORD | Q00796 | 6/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20745928 | 0.83 | NR1H2 (0.39) | NR1H2SORDEGFRHCRTR1HCRTR2 | |
| SCHEMBL20745099 | 0.82 | EGFR (0.37) | ACACBNR1H2SORDEGFRAOC3 | |
| SCHEMBL20745392 | 0.80 | NR1H2 (0.40) | NR1H2SORDHCRTR1HCRTR2 | |
| SCHEMBL31434276 | 0.79 | SORD (0.41) | NR1H2SORDHCRTR1HCRTR2 | |
| SCHEMBL22320481 | 0.77 | NR1H2 (0.39) | NR1H2SORDHCRTR1HCRTR2 | |
| SCHEMBL30068037 | 0.77 | ACACB (0.41) | ACACBEGFRKCNQ3KCNQ2HCRTR1 | |
| SCHEMBL20745292 | 0.77 | NR1H2 (0.36) | NR1H2SORDHCRTR1HCRTR2 | |
| SCHEMBL20745039 | 0.77 | NR1H2 (0.36) | NR1H2SORDHCRTR1HCRTR2 | |
| SCHEMBL20745396 | 0.77 | DYRK1A (0.39) | NR1H2SORDHCRTR1HCRTR2 | |
| SCHEMBL20745400 | 0.77 | HCRTR2 (0.39) | NR1H2SORDHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112739343-A | Macrocyclic MCL-1 inhibitors and methods of use | 艾伯维公司 | 2021-04-30 | — | — | CN | disclosed |
| US-20200255451-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2020-08-13 | — | — | US | disclosed |
| EP-3668504-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | AbbVie Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019035914-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC. (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255451-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | ACACB 3994/4885NR1H2 3570/4885SORD 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.